146 related articles for article (PubMed ID: 12080146)
1. Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.
Whiteside TL; Gambotto A; Albers A; Stanson J; Cohen EP
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9415-20. PubMed ID: 12080146
[TBL] [Abstract][Full Text] [Related]
2. Transfection of human monocyte-derived dendritic cells with native tumor DNA induces antigen-specific T-cell responses in vitro.
Artusio E; Hathaway B; Stanson J; Whiteside TL
Cancer Biol Ther; 2006 Dec; 5(12):1624-31. PubMed ID: 17172816
[TBL] [Abstract][Full Text] [Related]
3. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100.
Lapointe R; Royal RE; Reeves ME; Altomare I; Robbins PF; Hwu P
J Immunol; 2001 Oct; 167(8):4758-64. PubMed ID: 11591807
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
5. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
7. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells.
Prabakaran I; Menon C; Xu S; Gómez-Yafal A; Czerniecki BJ; Fraker DL
Ann Surg Oncol; 2002 May; 9(4):411-8. PubMed ID: 11986195
[TBL] [Abstract][Full Text] [Related]
8. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy.
Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH
Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632
[TBL] [Abstract][Full Text] [Related]
9. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
10. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
11. Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Nagorsen D; Panelli M; Dudley ME; Finkelstein SE; Rosenberg SA; Marincola FM
Gene Ther; 2003 Sep; 10(20):1754-65. PubMed ID: 12939642
[TBL] [Abstract][Full Text] [Related]
12. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
[TBL] [Abstract][Full Text] [Related]
13. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
[TBL] [Abstract][Full Text] [Related]
14. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.
Astsaturov I; Petrella T; Bagriacik EU; de Benedette M; Uger R; Lumber G; Berinstein N; Elias I; Iscoe N; Hammond C; Hamilton P; Spaner DE
Clin Cancer Res; 2003 Oct; 9(12):4347-55. PubMed ID: 14555505
[TBL] [Abstract][Full Text] [Related]
15. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
Lotem M; Zhao Y; Riley J; Hwu P; Morgan RA; Rosenberg SA; Parkhurst MR
J Immunother; 2006; 29(6):616-27. PubMed ID: 17063124
[TBL] [Abstract][Full Text] [Related]
16. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Touloukian CE; Leitner WW; Topalian SL; Li YF; Robbins PF; Rosenberg SA; Restifo NP
J Immunol; 2000 Apr; 164(7):3535-42. PubMed ID: 10725708
[TBL] [Abstract][Full Text] [Related]
17. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Topalian SL; Sherry RM; Restifo NP; Wunderlich JR; Seipp CA; Rogers-Freezer L; Morton KE; Mavroukakis SA; Gritz L; Panicali DL; White DE
Clin Cancer Res; 2003 Aug; 9(8):2973-80. PubMed ID: 12912944
[TBL] [Abstract][Full Text] [Related]
18. Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes.
Hu HM; Dols A; Meijer SL; Floyd K; Walker E; Urba WJ; Fox BA
J Immunother; 2004; 27(1):48-59. PubMed ID: 14676633
[TBL] [Abstract][Full Text] [Related]
19. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
[TBL] [Abstract][Full Text] [Related]
20. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]